Nurix Therapeutics, Inc. (NRIX)
| Market Cap | 562.33M |
| Revenue (ttm) | 34.36M |
| Net Income (ttm) | -135.45M |
| Shares Out | 44.95M |
| EPS (ttm) | -3.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 295,951 |
| Open | 11.50 |
| Previous Close | 11.60 |
| Day's Range | 11.00 - 12.56 |
| 52-Week Range | 7.52 - 37.43 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 42.13 (+236.8%) |
| Earnings Date | Jul 12, 2022 |
About NRIX
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-o... [Read more...]
Financial Performance
In 2021, NRIX's revenue was $29.75 million, an increase of 66.95% compared to the previous year's $17.82 million. Losses were -$117.19 million, 171.0% more than in 2020.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for NRIX stock is "Buy." The 12-month stock price forecast is 42.13, which is an increase of 236.77% from the latest price.
News
Nurix Therapeutics Will Present Trial in Progress Posters for Two Clinical Programs at the 2022 Annual European Hemat...
Posters provide background information and trial designs for ongoing clinical studies of wholly-owned NX-2127 and NX-5948 programs Posters provide background information and trial designs for ongoing cl...
Nurix Therapeutics Will Present Trial in Progress Posters for Three Clinical Programs at the Annual Meeting of the Am...
Posters provide background information and trial designs for ongoing clinical studies of wholly-owned NX-2127, DeTIL-0255, and NX-1607 programs Posters provide background information and trial designs f...
Nurix Therapeutics, Inc. (NRIX) Soars 14.5%: Is Further Upside Left in the Stock?
Nurix Therapeutics, Inc. (NRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the...
Nurix Therapeutics Announces Participation in the 2022 RBC Capital Markets Global Healthcare Conference
SAN FRANCISCO, May 11, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that Ar...
Nurix Therapeutics to Host R&D Day on May 26, 2022
Event will include guest speaker, Dr. Anthony Mato, Director of the CLL Program at Memorial Sloan Kettering Cancer Center Event will include guest speaker, Dr. Anthony Mato, Director of the CLL Program ...
Nurix Therapeutics Presents New Preclinical Data Supporting NX-2127 and DeTIL-0255 Clinical Programs at the American ...
Studies provide insight into bifunctional molecular mechanism and first in vivo demonstration of immunomodulatory imide drug (IMiD) activity of NX-2127, resulting in robust tumor cell killing
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates
Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of -6.74% and 9.68%, respectively, for the quarter ended February 2022. Do the numbers hold clues to what lies ahead for the stock?
Nurix Therapeutics Reports Fiscal First Quarter 2022 Financial Results and Provides a Corporate Update
Dosed first patient in the Phase 1 trial of DeTIL-0255, Nurix's drug-enhanced tumor infiltrating lymphocyte (TIL) program
Nurix Therapeutics Announces Participation in the 21st Annual Needham Virtual Healthcare Conference
SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that ...
Nurix Therapeutics Awarded Innovation Passport for Entry into Innovative Licensing and Access Pathway (ILAP) in the U...
NX-1607 is being evaluated in multiple immuno-oncology indications, including a range of solid tumor types
Nurix Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO, March 09, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands,...
Nurix Therapeutics to Present Preclinical Data from Its Novel BTK Degrader (NX-2127) and CBL-B Inhibitor (NX-0255) Pr...
SAN FRANCISCO, March 08, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that preclinical dat...
Nurix Therapeutics Announces Participation in the 11th Annual SVB Leerink Global Healthcare Conference
SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands,...
Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates
Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of -26.87% and 50.67%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the st...
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Corporate Update
Advanced four wholly owned and internally developed programs into clinical development
Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts
Nurix leads protein modulation field with four active clinical stage programs
Nurix Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, ...
Nurix Therapeutics Announces Regulatory Clearance to Initiate Phase 1 Clinical Trial of NX-5948 and Presents New Prec...
U.K. regulatory authorities grant Clinical Trial Authorization with dosing of first patient anticipated in the first half of 2022
Nurix Therapeutics Announces IND clearance for DeTIL-0255, a drug-enhanced autologous T cell therapy for the potentia...
Food and Drug Administration clears DeTIL-0255 to initiate Phase 1 clinical trial
Nurix Therapeutics Presents Beneficial Effects of CBL-B Inhibition on Human Tumor Infiltrating Lymphocytes at SITC Co...
DeTIL-0255 is a drug-enhanced investigational new cell therapy product candidate with potentially superior T cell properties compared to conventional TIL
Why Nurix Therapeutics Stock Soared More Than 21% Wednesday
The clinical-stage biopharmaceutical company posted positive news regarding its lead therapy -- a BTK inhibitor that could fight certain blood-based cancers.
Why Did SVB Leerink Beef Up Target Price For Nurix Therapeutics?
SVB Leerink raised the price target on Nurix Therapeutics Inc (NASDAQ: NRIX) to $64 from $50, with an Outperform rating, seeing an upside of almost 92%. Analyst Christopher Liu notes that Nurix presente...
Nurix Therapeutics Announces Initial Data from the First Phase 1a Dose Escalation Trial of NX-2127 in Patients with R...
Robust BTK target degradation achieved in all patients treated to date
Nurix Therapeutics to Present Initial Target Degradation Data from First Phase 1 Trial of NX-2127 in B Cell Malignanc...
Presentation to include initial pharmacokinetic and BTK degradation data
Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Tops Revenue Estimates
Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of 1.52% and 17.49%, respectively, for the quarter ended August 2021. Do the numbers hold clues to what lies ahead for the stock?